Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Conatus Pharmaceuticals Inc (NASDAQ:CNAT)

2.18
Delayed Data
As of 4:00pm ET
 +0.12 / +5.83%
Today’s Change
1.40
Today|||52-Week Range
7.12
-24.31%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$43.8M

Company Description

Conatus Pharmaceuticals, Inc. is a biotechnology company engages in the development and commercialization of medicines to liver diseases treatment. It focuses in development of Emricasan, orally active protease inhibitor designed to reduce the activity of enzymes that mediate inflammation and cell death or apoptosis for the interruption of progress of liver disease. The company was founded by Alfred P. Spada, Jennifer Giottonini Cayer, Steven J. Mento and Charles J. Cashion on July 13, 2005 and is headquartered in Dan Diego, CA.

Contact Information

Conatus Pharmaceuticals, Inc.
16745 West Bernardo Drive
San Diego California 92127-7619
P:(858) 376-2600
Investor Relations:
(858) 376-2637

Employees

Shareholders

Mutual fund holders8.73%
Individual stakeholders36.39%
Other institutional12.73%

Top Executives

Steven J. MentoPresident, Chief Executive Officer & Director
Charles J. CashionChief Financial Officer, Secretary & SVP-Finance
Alfred P. SpadaCSO, EVP-Research & Development
Daniel L. RipleyVP-Business Development & Program Management
David T. HagertyExecutive Vice President-Clinical Development